Novartis and Ionis cholesterol trial falls short in late-stage setback
Novartis and Ionis’ late-stage cholesterol program fell short, weakening a major clinical bet for both companies. The result shifts attention to the program’s commercial prospects and to Ionis’ ability to offset pipeline risk with its broader portfolio.
STOCK PHOTO · FABIO RICCOBONOThe story
The late-stage trial outcome affects Novartis and Ionis’ cholesterol collaboration, but the specific efficacy, safety and regulatory details are not established here. The program was positioned as a significant bet for both companies, making the shortfall a direct setback for a potentially important development asset.
Ionis reported FY2025 revenue of $943.7M, up 33.8% year over year, alongside a net loss of 40.4% of revenue and diluted EPS of $-2.38. Those figures provide financial context for the pipeline setback, but they are annual company figures and do not quantify the program’s contribution or the effect of this trial on future revenue.
For Novartis, the mechanism is pipeline optionality: a disappointing late-stage cholesterol result reduces the value of this particular cardiovascular opportunity. For Ionis, the link is more direct because the company’s economics depend on advancing and commercializing partnered medicines; the trial outcome therefore adds pressure to the rest of its development portfolio.
The size of the setback remains uncertain because the trial’s endpoint performance, safety profile, next regulatory step and partnership response are not established in the available reporting. Those details would determine whether the program is abandoned, redesigned or retained for a narrower use.
The next evidence to watch is a fuller clinical disclosure from the companies, including the primary endpoint result, safety findings and any decision on further development. Ionis’ next quarterly update will also show whether management changes its pipeline or financial framing after the result.
Our read · Thu, Sep 17
Novartis (NVS) and Ionis (IONS)’ late-stage cholesterol program fell short.
Why. The immediate consequence is reduced value in a partnered late-stage asset, with Ionis more exposed because its FY2025 profile still included a $-2.38 diluted EPS loss and a -40.4% net margin. The trade read stays non-directional until the companies disclose the endpoint, safety and development path, because those details decide whether this is a terminal failure or a narrower commercial setback.
Both cases
What could change this view: A favorable full data release, a viable follow-on development plan or evidence that the program was financially immaterial could blunt the pipeline impact.
Who reported it · 2
Since this story · the companies named here, equal weight · −17.2%
Price context does not establish that the story caused the move.
Keep reading
More on IONS
Astra falls 9% after Wainua misses primary endpoint in late-stage trialLatest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by Yahoo Finance as Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
, . Who answers for this
2 reports from 1 publisher in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →